DiaPep277 (DeveloGen).
DiaPep277, a 24-amino acid peptide based on residues 437 to 460 of heat shock protein 60, is undergoing phase II clinical trials by DeveloGen for the potential treatment and prevention of established and newly diagnosed type 1 diabetes symptoms of the prediabetic state and of latent autoimmune diabetes of the adult.
Giannoukakis
Nick
N
University of Pittsburgh School of Medicine, Diabetes Institute, Pittsburgh, PA 15213, USA. ngiann1@pitt.edu
D000818:Animals; D018834:Chaperonin 60; D017322:Clinical Trials, Phase II as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004345:Drug Industry; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use*; D010446:Peptide Fragments; D010455:Peptides / Q000737:chemistry / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
D018834:Chaperonin 60; C447781:DiaPep 277; D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D010455:Peptides